A Phase 1/2 Study of MEDI4276 in Adults Subjects with Select HER2-expressing Advanced Solid Tumors.

Trial Identifier: D5760C00001
Sponsor: MedImmune, LLC
NCTID:: NCT02576548
Start Date: September 2015
Primary Completion Date: May 2018
Condition: Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation

Trial Locations

Country Location
United States of America, CA Stanford, CA, United States of America, 94305
United States of America, FL Sarasota, FL, United States of America, 34232
United States of America, IN Indianapolis, IN, United States of America, 46202
United States of America, NC Charlotte, NC, United States of America, 28204
United States of America, TN Nashville, TN, United States of America, 37203